Abstract
In March 2020, the U.S. Food and Drug Administration (FDA) required a Black Box Warning for montelukast due to serious mental health side effects. We hypothesized that the warning would lead to an overall decrease in reports of mental health symptoms and disorders related to montelukast use among pediatric patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
